(Q80316010)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495867%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

review article

1 reference

title

HMG-CoA reductase inhibitors and the kidney (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495867%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495867%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Campese VM

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495867%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

language of work or name

English

0 references

publication date

9 May 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495867%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495867%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

71

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495867%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495867%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

1215-1222

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495867%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.ki.5002174

30 December 2019

exact match

0 references

cites work

HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Undertreatment of hyperlipidemia in a cohort of United States kidney dialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Focal and segmental glomerulosclerosis: analogies to atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Lipids and the kidney

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Mild renal insufficiency is associated with reduced coronary flow in patients with non-obstructive coronary artery disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Association between carotid artery intima-media thickness and cardiovascular risk factors in CKD.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Cellular lipid metabolism and the role of lipids in progressive renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

LDL stimulates mesangial fibronectin production and chemoattractant expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Transcription factor-kappa B (NF-kappa B) and renal disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Molecular Pathways of Endothelial Cell Activation for (Targeted) Pharmacological Intervention of Chronic Inflammatory Diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Statins and their role in vascular protection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Modulation of the inflammatory process by statins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Noncholesterol-Lowering Effects of Statins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Human mesangial cell production of monocyte chemoattractant protein-1: modulation by lovastatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Pravastatin suppress superoxide and fibronectin production of glomerular mesangial cells induced by oxidized-LDL and high glucose

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

HMG-CoA reductase inhibition aborts functional differentiation and triggers apoptosis in cultured primary human monocytes: a potential mechanism of statin-mediated vasculoprotection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Hmg-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Endothelium-dependent effects of statins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Atorvastatin improves endothelial function in renal-transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Role of nitric oxide in inflammatory conditions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Cellular antioxidant effects of atorvastatin in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Atorvastatin improves the course of ischemic acute renal failure in aging rats.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Effect of simvastatin on proliferative nephritis and cell-cycle protein expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Statin monotherapy attenuates renal injury in a salt-sensitive hypertension model of renal disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Effects of hypertension and dyslipidemia on the decline in renal function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Effect of lipid reduction on the progression of renal disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Rosuvastatin-induced arrest in progression of renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Study of Heart and Renal Protection (SHARP)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

The effect of pravastatin on acute rejection after kidney transplantation--a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Risk factors predicting chronic rejection of renal allografts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Effect of pravastatin on outcomes after cardiac transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Impact of statin treatment on 1-year functional and histologic renal allograft outcome.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

The effects of lipid-lowering agents on acute renal allograft rejection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Risk for myopathy with statin therapy in high-risk patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Anti-inflammatory effects of statins: clinical evidence and basic mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002174

7 January 2021

Identifiers

DOI

10.1038/SJ.KI.5002174

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17495867%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

30 December 2019

0 references

1 reference